Calando Presents Data on Cancer Drug Candidate In Monkeys, Reaffirms Timeline for Human Trial

/Home/Biologics Delivery - Protein Synthesis/RNA - Protein Synthesis/RNAi - Protein Synthesis

Calando Presents Data on Cancer Drug Candidate In Monkeys, Reaffirms Timeline for Human Trial
October 26, 2006
By Doug Macron
RNAi News
Calando CSO Jeremy Heidel presented data demonstrating that the company?s lead cancer drug candidate is well-tolerated at certain doses in non-human primates. He also reaffirmed the company?s goal of getting the drug into the clinic in the second half of 2007.
Paid subscription is required to view article.